title: Neuroprotective action of proline-rich polypeptide-1 in β-amyloid induced neurodegeneration in rats.
abstract: It is recognized that the main trigger of Alzheimer disease related neurodegeneration is β-amyloid peptide, which subsequently generates different metabolic disorders in neuron and finally leads to neuronal death. Several biologically active products were tested as neuroprotectors, but only few of them demonstrated any efficiency. Proline-rich polypeptide-1 was tested as a neuroprotective agent on Aβ25-35 animal model of Alzheimer disease. Biochemical analysis (determination of spectrum of neuroactive amino acids, such as glutamate, gamma-aminobutyric acid, glycine, aspartate and taurine), as well as behavioral, electrophysiological and morphological studies were performed to reveal the neuroprotective potential of proline-rich polypeptide in rats. Based on the results of our study it can be concluded that proline-rich polypeptide-1 has a potential to be one of the effective preventive or therapeutic agents against neurodegenerative disorders, such as Alzheimer disease.
authors.affiliation: Department of Biochemistry, Yerevan State Medical University, Yerevan, Armenia. enkoyan@yahoo.com
authors.forename: Konstantin
authors.initials: K
authors.lastname: Yenkoyan
authors.forename: Karen
authors.initials: K
authors.lastname: Safaryan
authors.forename: Vergine
authors.initials: V
authors.lastname: Chavushyan
authors.forename: Irina
authors.initials: I
authors.lastname: Meliksetyan
authors.forename: Grizelda
authors.initials: G
authors.lastname: Navasardyan
authors.forename: John
authors.initials: J
authors.lastname: Sarkissian
authors.forename: Armen
authors.initials: A
authors.lastname: Galoyan
authors.forename: Michail
authors.initials: M
authors.lastname: Aghajanov
mesh_terms: D000596:Amino Acids / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D000818:Animals; D023181:Antimicrobial Cationic Peptides; D001007:Anxiety / Q000523:psychology; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000473:pathology; D002540:Cerebral Cortex / Q000378:metabolism / Q000473:pathology; D002851:Chromatography, High Pressure Liquid; D003342:Corpus Striatum / Q000378:metabolism / Q000473:pathology; D004569:Electroencephalography; D055724:Electrophysiological Phenomena; D006624:Hippocampus / Q000378:metabolism / Q000473:pathology; D007276:Injections, Intraventricular; D008297:Male; D019636:Neurodegenerative Diseases / Q000139:chemically induced* / Q000517:prevention & control* / Q000523:psychology; D018696:Neuroprotective Agents; D010446:Peptide Fragments / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D010455:Peptides / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000596:Amino Acids; D016229:Amyloid beta-Peptides; D023181:Antimicrobial Cationic Peptides; D018696:Neuroprotective Agents; C540268:PRP-1 peptide; D010446:Peptide Fragments; D010455:Peptides; C074636:amyloid beta-protein (25-35)